DSAEK vs DMEK: Comparing Modern Corneal Transplant Techniques

When the cornea's innermost layer fails—as in Fuchs' endothelial dystrophy or bullous keratopathy—selective endothelial keratoplasty has replaced traditional full-thickness corneal transplantation as the standard of care. Two techniques dominate this field: DSAEK and DMEK. Both achieve the same goal of replacing diseased endothelial cells, but they differ in important ways that affect visual outcomes, recovery, and suitability for different patients.

DSAEK: The Established Technique

DSAEK (Descemet Stripping Automated Endothelial Keratoplasty) involves transplanting a disc of donor tissue comprising the endothelium, Descemet's membrane, and a thin layer of posterior stroma—typically 100 to 150 microns thick. The donor tissue is inserted through a small incision and positioned against the recipient's posterior cornea using an air bubble that holds the graft in place while it adheres naturally over the following hours and days.

DSAEK represented a major advance over penetrating keratoplasty, eliminating the need for full-thickness sutures, reducing rejection risk substantially, and accelerating recovery from years to months. Visual outcomes are good, with most patients achieving driving-standard acuity within three to six months. However, the residual donor stroma creates a subtle optical interface within the cornea that can limit best-corrected visual acuity—typically achieving 6/9 to 6/12 rather than 6/6.

The additional stromal tissue also means the donor graft is slightly thicker, which can cause a small hyperopic (long-sighted) shift that needs to be factored into IOL calculations if cataract surgery is performed simultaneously.

DMEK: The Refined Evolution

DMEK (Descemet Membrane Endothelial Keratoplasty) transplants only the endothelium and Descemet's membrane—a tissue layer just 10 to 15 microns thick, roughly one-tenth the thickness of a DSAEK graft. By eliminating the additional stromal layer, DMEK removes the optical interface that limits visual outcomes in DSAEK. The result is faster visual recovery and superior final acuity, with over 50% of DMEK patients achieving 6/6 vision—a rate significantly higher than DSAEK achieves.

DMEK also carries a lower rejection rate than DSAEK, likely because the transplanted tissue volume is substantially smaller, presenting less foreign material to the recipient's immune system. Published studies show rejection rates of approximately 1% for DMEK compared to 6-8% for DSAEK at five years. This has implications for long-term graft survival and the intensity of immunosuppressive drop therapy required.

The Trade-Off: Surgical Complexity

The thinner DMEK tissue is considerably more technically demanding to handle, prepare, and position. The graft scrolls naturally into a tight roll and must be carefully unfolded inside the eye—a step that requires significant surgical experience and dexterity. Re-bubbling rates (requiring an additional air injection to keep the graft attached) are higher with DMEK, occurring in roughly 15-30% of cases in published series, though this decreases significantly with surgeon experience.

DSAEK tissue is thicker, more robust, and more forgiving during surgery. It does not scroll and is easier to manipulate into position. This makes it a reliable option when anatomical factors make DMEK challenging—for example, in eyes with previous glaucoma surgery, anterior chamber intraocular lenses, aphakia, or complex anterior segment anatomy that complicates DMEK tissue handling.

Combined Surgery with Cataracts

Many patients with endothelial disease also have cataracts, and both DSAEK and DMEK can be combined with cataract surgery in a single procedure—known as a triple procedure. This avoids the need for two separate operations and allows the IOL power to be calculated accounting for the refractive effect of the transplant. Ms Menassa routinely performs combined procedures, selecting the transplant technique best suited to each patient's anatomy.

Which Technique Is Right for You?

For most patients with straightforward endothelial disease, DMEK offers the best visual outcome with the lowest rejection risk. It is the technique Ms Menassa performs most frequently, drawing on her fellowship training in Germany and Switzerland where DMEK was developed and refined. However, clinical judgment is essential—some eyes are better served by DSAEK, and a surgeon experienced in both techniques can make the right recommendation based on your individual anatomy, visual needs, and circumstances. The decision is always made collaboratively, with full explanation of the reasoning.